Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Question: Which of the three drugs has garnered the most attention? "we are fortunate that all three of our drug candidates have appealed to partnering opportunities". "It's more prudent for us to take into consideration for what a partner wants and make that happen". "During past few months we've engaged in more business development and had more high level meetings then anytime in company's history". "we maintain ongoing discussions with multiple potential corporate partners and also continue to develop new relationships to that point we've signed CDA's with some of the largest pharmas and biotech's.
Sounds like big pharma may be advising behind the scenes.
No word was mentioned regarding the material transfer agreements with university laboratories. Also no update regarding MTA with the large pharmaceutical. I know we were updated at one time that the large pharma had requested more compound. Sure would be nice to know how that collaboration is going.
Wrong board??eom
Great price momentum. Election spawned new buying for ctix the little pharma that could. Buyers are seeing the great opportunity longs have watched mature. Great pipeline, multiple trials, positive results are bringing in new and returning buyers, slow at first but then lots of fun when the flood gates open. Hopefully it's enough to spur uplisting. Lot's of stuff happening. Positive P2b interim data will be more icing on the cake.
Evidence has been provided proving in fact cellceutix is a real company with a real drug pipeline in real multiple ongoing FDA trials. Many invested here have been here for years and have seen many just like you come along announcing scam and like them you too will fade away just like the all politicians after election.
You called this company a scam so why stick around or even give a rats behind about 5yrs. Except you know this company is not a scam and with every trial approval the potential for longs to see hyper price appreciation is now only weeks or a few months away. Ctix trials will have the last word not basement pundits.
Cempra antibiotic seen as toxic and yet gets FDA pass. Brilacidin should pass FDA panel with flying colors when it gets through phase3.
https://www.washingtonpost.com/politics/fda-panel-narrowly-backs-cempra-antibiotic/2016/11/04/9ea9f8f0-a2d4-11e6-8864-6f892cad0865_story.html
Yes and if it wasn't for "them" shareholders wouldn't have been screwed over by a lying hit piece and then the company spending money defending itself in a lawsuit cooked up by a so called law firm.
We already had very positive results at lower dose. Surely a pill that can alleviate or even go as far as cure plaque psoriasis has the makings of a big deal. I would bet Dr Bertolino made this known to big pharma and they going to be closely watching p2 escalated dosage trial closely.
Yes agree a lot riding on 52 week data.
9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) DECEMBER 8-10, 2016.
Oral Session, Saturday Dec10 8.45 a.m OC59 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients.
Probably this: "Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001" 10/16
Delivery device agreement very positive for AIR001. Phase2 update promised 4th quarter.
Patients take their set dosing for a full 12 weeks. Patient enrollment is staggered.
I do not know the answer to your question as to interim patient count. We should get patient analysis on all subsets though.
6 week interim, half way point mid March.
Ctix a gift from God..Remember. Science says plenty of green up ahead.
Yes. Reducing costs adding value. Prurisol a winner here.
"Overall analyses showed Prurisol, which is being developed under the FDA’s 505(b)(2) program, to be superior to placebo in the 200mg arm. Pharmacokinetics/Pharmacodynamics (PK/PD) further revealed an early (by week 8) dose-related response that improved as treatment duration increased".
Clearly more Prurisol is even better. Let's get P2b underway.
Believe me historical pricing of Regeneron years back shows the same growing pains. Ctix trials themselves have been very positive and only setback was one contrived from person or persons who write lying distorted articles scaring the hell out of old and new investors.
Exactly. My understanding is any treatment other then radiation treatment prior to entering OM disqualifies the candidate.
Favorable UP/UPS pk profile supports positive OM trial. So far they have not been wrong.
From his quick copy/paste I would say he is well versed in the short article. Hopefully Ashcroft and Co. is looking for Mako water carriers.
B for ABSSSI has been proven to work in single dose and is still worth the $4 dollars FDA QIDP got us.
Seems PR blackout makes it hard for flippers. Less is more here. Looking forward to great news update just around the corner though.
Application soon..
Upcoming:
-Q4 2016 / Q1 2017 File application for CE Mark for EU commercialization authorization
2017 Milestones:
-Receive CE Mark
-Commence EU internal surgical clinical trial
-Commence US clinical trial
-File additional patent application(s)
-Commence commercialization
-Advance product pipeline
It was a blog post not as widely disseminated. Looking for a Air001 Phase 2 company update soon.
NBC nightly news. Prayers go out to that little girl.
http://www.nbcnews.com/health/cancer/young-woman-hopes-pioneering-study-her-genetic-cancer-risk-will-n670156
It's how small bio's do it. Hopefully P 2b gets underway soon.
All dilutive.
Honest answer. I hope the CEO clues us in real soon where he will get funding.
You came up short.
Per Dr Bertolino "Since successfully completing the initial Phase 2 trial of oral Prurisol for mild to moderate plaque psoriasis, the Company has fielded inquiries from many interested parties about the compound and has evaluated several options for the next stage of development".
Phase2b to start this quarter. Should see PR with next stage of development soon. Market will soon get it.
So were getting a look at 36 and 52 week efficacy outcome.
CTAD 2016
Anavex Saturday December 10
8:45am Oral Session OC-59
http://www.ctad-alzheimer.com/sites/ctad.prod/files/files/PROGRAMprel_CTAD2016_7oct.pdf
Yes thanks. I jumped the gun. Prelim list not out yet.
ARCH presenting at Biotech showcase in January.
http://www.ebdgroup.com/bts/core/presenting-companies.php?_ga=1.167820066.2013261688.1476239046
Probably in fits and starts.
Paying a million dollar note off a year early is definitely a huge vote of confidence. Sounds like a deal coming.
Sweet move up at the end. After again reviewing latest webcast added yesterday.
This is not some no name pharma, but a huge deep pocket well regarded company. This collaboration is a huge plus for AVXL.